Search the Newsreel

Rezolute, Inc. (RZLT) gains 5.9% reported stake from Dellora Investments

Dellora Investments Master Fund LP, Dellora Investments LP, and Kevin Pyun have reported significant beneficial ownership in Rezolute, Inc. (RZLT). Dellora Investments Master Fund LP holds a 5.1% stake, while Dellora Investments LP and Kevin Pyun each reported a 5.9% stake, based on shared …

Rezolute Inc (RZLT) Earnings Forecast: Future EPS & Revenue Growth Estimates

Rezolute Inc (RZLT) currently has an earnings forecast score of 8.40, ranking it 131st in the Biotechnology & Medical Research industry. Analysts have set an average price target of $17.00 for RZLT, with a high of $20.00 and a low of $12.00. The consensus …

Rezolute Inc (RZLT) Stock News Today

This article from TradingKey provides current stock news for Rezolute Inc (RZLT), including its stock price, market cap, and links to financial data, analyst ratings, and ownership information. It notes that more news is coming soon, encouraging users to stay tuned for updates.

H.C. Wainwright reiterates Rezolute stock rating at buy, $5 target By Investing.com

H.C. Wainwright has reiterated a Buy rating for Rezolute (NASDAQ:RZLT) with a $5.00 price target, noting the company's ersodetug program holds significant potential. The firm expects FDA clarity on congenital hyperinsulinism in 2-3 months and a readout for tumor-induced hyperinsulinism by year-end, with each …

Rezolute Inc (RZLT) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Rezolute Inc (RZLT), stating its current valuation score is 6.24. It notes the company's P/E ratio is -6.04, which is significantly below its recent high and above its recent low. The article also mentions that relevant data …

Rezolute Inc (RZLT) Cash Flow

This article provides a detailed historical overview of Rezolute Inc.'s (RZLT) cash flow statements, including operating, investing, and financing activities. It presents quarterly and annual data with percentage changes from Q1 FY2012 through Q3 FY2026. The data allows users to evaluate the company's financial …

RZLT|Rezolute Inc|Price:4.930|Chg%:-0.060

Rezolute Inc (RZLT) shows weak fundamentals but high growth potential, with its valuation assessed as fairly valued. Institutional ownership is very high, and analysts largely rate it as a "Buy" with an expected upward trend in the medium term. The company is focused on …

Rezolute Inc (RZLT) Balance Sheet

This article provides a detailed balance sheet for Rezolute Inc (RZLT), offering both quarterly and annual financial data. It highlights key financial figures such as cash and short-term investments, total assets, liabilities, and shareholders' equity, along with their year-over-year percentage changes. The article also …

Rezolute Inc (RZLT) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Rezolute Inc (RZLT), detailing various metrics related to volatility, financial risk, and investment risk. It presents data on beta, Value at Risk (VaR), maximum drawdown, volatility, return statistics, Sharpe Ratio, skewness, downside risk-adjusted return, and liquidity. The …

Rezolute Inc (RZLT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Rezolute Inc (RZLT), focusing on its current stock price, support and resistance levels, and various technical indicators and moving averages. It highlights that the stock is currently trading between resistance at $5.56 and support at $4.28, suggesting …

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

Rezolute, Inc. (Nasdaq: RZLT), a company specializing in treating refractory hypoglycemia caused by hyperinsulinism, announced its participation in the BTIG Virtual Biotechnology Conference on July 28-29, 2026. Management will hold one-on-one investor meetings at the event. Investors interested in meeting with Rezolute should contact …

Rezolute Management to Meet Investors Online July 28-29

Rezolute (Nasdaq: RZLT) announced that its management team will attend the BTIG Virtual Biotechnology Conference on July 28-29, 2026, for one-on-one investor meetings. The company, a late-stage ultra-rare disease firm, focuses on treating refractory hypoglycemia from hyperinsulinism and is developing the antibody therapy ersodetug. …

Is Rezolute (NASDAQ:RZLT) In A Good Position To Deliver On Growth Plans?

This article analyzes Rezolute's financial health and its potential to fund future growth. It examines the company's cash burn rate, non-operating cash flow, and debt levels to assess its financial runway without needing to raise additional capital soon. The analysis suggests Rezolute might need …

Price to earnings forward of Rezolute, Inc. – NASDAQ:RZLT

RZLT Forecast — Price Target — Prediction for 2027

Jefferies Raises Rezolute Target to Spur Stock Optimism

Jefferies Raises Rezolute Price Target Amid Favorable Data Prospects

Rezolute Inc. (RZLT) Stock Price | Live Quotes & Charts | NASDAQ